A complete application in a minute
Tailored resume and cover letter, ready to send.
DBV Technologies in Warren, NJ seeks a Brand Counsel to serve as legal advisor to the cross-functional brand team, supporting pre-launch and commercialization activities, reviewing materials for FDA compliance and drafting contracts with payors, pharmacies, and other partners.
You will lead clearance on promotional and non-promotional materials, advise sales and marketing teams on advertising, and manage outside counsel as needed while collaborating across time zones and functions to advance our
Brand Counsel will serve as legal advisor and strategic partner to the Company’s cross-functional brand team, providing day-to-day legal guidance to the sales, marketing, market access, and medical affairs teams in support of both pre-launch preparation and ongoing commercialization activities. The Brand Counsel will serve as a legal reviewer on the promotional review committee and medical review committee, reviewing promotional, non-promotional, and scientific materials for compliance with FDA regulations and other applicable laws, and will lead the drafting and negotiation of contracts with the Company’s customers (including, without limitation, payors, pharmacies, and other trade partners).
Warren, New Jersey - minimum 3 days on site
$250-290k
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively.
We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need.
This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin.
Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy.
Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.